Stabilization of eye drops containing autologous serum and recombinant human epidermal growth factor for dry eye syndrome
Copyright: © 2020 Journal of Advanced Pharmaceutical Technology & Research..
Human epidermal growth factor (hEGF) and autologous serum are considered safer and more effective in treating dry eye syndrome. However, suitable formulas and preparation methods are needed to obtain eye drop containing autologous serum and hEGF, which are stable during storage and use. Therefore, this study aimed to develop a stable and effective eye drops containing autologous serum and hEGF. Stabilization of autologous serum and hEGF was done by adding lyoprotectant and antioxidant agents, and then prepared using the freeze-drying method. The clarity, pH, sterility, and endotoxin content of the preparation were evaluated. The effectiveness of the preparation was assessed by a cell viability test using a WST-8 reagent. Based on the results, all formulas produce preparations that are isotonic, clear, sterile, stable, and free from endotoxins. Cell viability test shows the addition of 25 μg/mL hEGF increased epithelial cell proliferation by up to 197%. It can be concluded that eye drops containing autologous serum and 25 μg/mL hEGF can be a promising therapy for dry eye syndrome.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Journal of advanced pharmaceutical technology & research - 11(2020), 4 vom: 08. Okt., Seite 184-188 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sriwidodo, Sriwidodo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Autologous serum |
|---|
| Anmerkungen: |
Date Revised 12.01.2021 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4103/japtr.JAPTR_72_20 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319892131 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319892131 | ||
| 003 | DE-627 | ||
| 005 | 20231226202423.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4103/japtr.JAPTR_72_20 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1066.xml |
| 035 | |a (DE-627)NLM319892131 | ||
| 035 | |a (NLM)33425702 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sriwidodo, Sriwidodo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Stabilization of eye drops containing autologous serum and recombinant human epidermal growth factor for dry eye syndrome |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 12.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright: © 2020 Journal of Advanced Pharmaceutical Technology & Research. | ||
| 520 | |a Human epidermal growth factor (hEGF) and autologous serum are considered safer and more effective in treating dry eye syndrome. However, suitable formulas and preparation methods are needed to obtain eye drop containing autologous serum and hEGF, which are stable during storage and use. Therefore, this study aimed to develop a stable and effective eye drops containing autologous serum and hEGF. Stabilization of autologous serum and hEGF was done by adding lyoprotectant and antioxidant agents, and then prepared using the freeze-drying method. The clarity, pH, sterility, and endotoxin content of the preparation were evaluated. The effectiveness of the preparation was assessed by a cell viability test using a WST-8 reagent. Based on the results, all formulas produce preparations that are isotonic, clear, sterile, stable, and free from endotoxins. Cell viability test shows the addition of 25 μg/mL hEGF increased epithelial cell proliferation by up to 197%. It can be concluded that eye drops containing autologous serum and 25 μg/mL hEGF can be a promising therapy for dry eye syndrome | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Autologous serum | |
| 650 | 4 | |a dry eye syndrome | |
| 650 | 4 | |a lyophilization | |
| 650 | 4 | |a recombinant human epidermal growth factor | |
| 700 | 1 | |a Kurniawan Syah, Insan Sunan |e verfasserin |4 aut | |
| 700 | 1 | |a Maksum, Iman Peramana |e verfasserin |4 aut | |
| 700 | 1 | |a Subroto, Toto |e verfasserin |4 aut | |
| 700 | 1 | |a Zasvia, Ulvi |e verfasserin |4 aut | |
| 700 | 1 | |a Umar, Abd Kakhar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of advanced pharmaceutical technology & research |d 2012 |g 11(2020), 4 vom: 08. Okt., Seite 184-188 |w (DE-627)NLM216708958 |x 2231-4040 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2020 |g number:4 |g day:08 |g month:10 |g pages:184-188 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4103/japtr.JAPTR_72_20 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2020 |e 4 |b 08 |c 10 |h 184-188 | ||